Faculty of Medicine, McGill University, Montreal, QC, Canada.
Division of Pediatric Allergy, Immunology, and Dermatology, Montreal Children's Hospital, Montreal, QC, Canada.
Pediatr Allergy Immunol. 2022 Mar;33(3):e13751. doi: 10.1111/pai.13751.
Cold urticaria (coldU) is associated with substantial morbidity and risk of fatality. Data on coldU in children are sparse. We aimed to evaluate the clinical characteristics, management, risk of associated anaphylaxis, and resolution rate of coldU in a pediatric cohort. Additionally, we sought to compare these metrics to children with chronic spontaneous urticaria (CSU).
We prospectively enrolled children with coldU from 2013-2021 in a cohort study at the Montreal Children's Hospital and an affiliated allergy clinic. Data for comparison with participants with solely CSU were extracted from a previous study. Data on demographics, comorbidities, severity of presentation, management, and laboratory values were collected at study entry. Patients were contacted yearly to assess for resolution.
Fifty-two children with cold urticaria were recruited, 51.9% were female and the median age of symptom onset was 9.5 years. Most patients were managed with second-generation H1-antihistamines (sgAHs). Well-controlled disease on sgAHs was negatively associated with concomitant CSU (adjusted odds ratio (aOR) = 0.69 [95%CI: 0.53, 0.92]). Elevated eosinophils were associated with cold-induced anaphylaxis (coldA; aOR = 1.38 [95%CI: 1.04, 1.83]), which occurred in 17.3% of patients. The resolution rate of coldU was 4.8 per 100 patient-years, which was lower than that of CSU (adjusted hazard ratio = 0.43 [95%CI: 0.21, 0.89], p < 10 ).
Pediatric coldU bears a substantial risk of anaphylaxis and a low-resolution rate. Absolute eosinophil count and co-existing CSU may be useful predictive factors.
冷荨麻疹(coldU)与大量发病率和死亡率相关。儿童冷荨麻疹的数据很少。我们旨在评估儿科队列中冷荨麻疹的临床特征、管理、相关过敏反应的风险和缓解率。此外,我们还试图将这些指标与慢性自发性荨麻疹(CSU)患儿进行比较。
我们在 2013 年至 2021 年期间,在蒙特利尔儿童医院和附属过敏诊所进行了一项前瞻性冷荨麻疹患儿队列研究。与仅患有 CSU 的参与者进行比较的数据是从之前的一项研究中提取的。研究开始时收集了有关人口统计学、合并症、发病严重程度、管理和实验室值的数据。每年联系患者以评估缓解情况。
招募了 52 名冷荨麻疹患儿,其中 51.9%为女性,症状发作的中位年龄为 9.5 岁。大多数患者接受第二代 H1 抗组胺药(sgAHs)治疗。sgAHs 控制良好的疾病与同时患有 CSU 呈负相关(调整后的优势比(aOR)= 0.69 [95%CI:0.53,0.92])。嗜酸性粒细胞升高与冷诱导过敏反应(coldA;aOR = 1.38 [95%CI:1.04,1.83])相关,17.3%的患者发生了 coldA。冷荨麻疹的缓解率为每 100 患者年 4.8 例,低于 CSU(调整后的危险比= 0.43 [95%CI:0.21,0.89],p < 10)。
儿科冷荨麻疹发生过敏反应的风险较大,缓解率较低。绝对嗜酸性粒细胞计数和并存的 CSU 可能是有用的预测因素。